NewcelX Ltd. Raises $1.55M in Private Placement for Diabetes Drug Development

NewcelX Ltd. announced a private placement financing, entering into securities purchase agreements with accredited investors to raise $1.55 million in gross proceeds. The financing involves the sale of common shares and common warrants. The company intends to use the net proceeds, along with its current cash and a previously announced equity line, primarily to advance its lead program NCEL-101 for type 1 diabetes, including initiating FDA-required toxicology studies, enhancing cell manufacturing, and preparing for a Phase 1/2a clinical trial in 2027. The offering is anticipated to close on or about November 23, 2026.